falsefalse

Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies - Episode 10

Diagnositc Feasibility: Liquid Biopsy vs Tissue Biopsy for Diagnostic Testing

A panelist discusses how although liquid biopsy offers potential advantages in terms of convenience and repeatability, tissue biopsy remains the current standard for MAGE-A4 testing because of the need for accurate protein expression assessment and established validation protocols, though ongoing research may eventually support complementary use of liquid biopsy approaches.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis
    EP. 2: Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel
    EP. 3: SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety
    EP. 4: Afami-cel Approval and Its Potential Influence on the Adoption of TCR Therapies
    EP. 5: Key Differences in T-Cell Response Therapy vs CAR T Therapy
    EP. 6: Optimal Timing for Introducing Afami-Cel Therapy in the Treatment Journey
    EP. 7: Sequencing Strategies of Afami-Cel With Chemotherapy and Targeted Therapies
    EP. 8: Addressing Potential Barriers to the Adoption of Afami-Cel Therapy
    EP. 9: Best Practices for HLA and MAGE-A4 Testing
    Now Viewing
    EP. 10: Diagnositc Feasibility: Liquid Biopsy vs Tissue Biopsy for Diagnostic Testing
    EP. 11: Approaches to First-Line Treatment for Synovial Sarcoma
    EP. 12: Potential Impact of Afami-Cel Therapy on the Standard of Care for R/R Cases
    EP. 13: Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens
    EP. 14: Logistical Considerations for Delivering TCR Therapy to Patients
    EP. 15: Comparing Afami-Cel Outcomes With Chemotherapy and Other Treatment Options
    EP. 16: Future Perspectives on TCR Therapies for Sarcomas and Other Solid Tumors

    Video content above is prompted by the following:

    What are your thoughts on the feasibility of using liquid biopsy vs tissue biopsy for diagnostic or eligibility testing?

    Related Content:

    Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted TherapiesClinicalInsightsVideo SeriesSarcomas
    Future Considerations for Treatment Sequencing in B-ALL
    Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center
    Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL
    x